G
o
o
g
l
e
×
Please click
here
if you are not redirected within a few seconds.
All
News
Images
Videos
Maps
Shopping
Books
Search tools
Recent
Recent
Past hour
Past 24 hours
Past week
Past month
Past year
Archives
Sorted by relevance
Sorted by relevance
Sorted by date
Alcon's $770M Aerie takeover delivers phase 3 dry eye wins
Fierce Biotech
The lead candidate in the acquired pipeline met the primary phase 3 endpoint, positioning Alcon to file for FDA approval in the middle of...
2 months ago
Have Insiders Been Selling Aerie Pharmaceuticals, Inc. (NASDAQ:AERI) Shares This Year?
Yahoo Movies UK
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly.
1 week ago
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Business Wire
(NASDAQ: AERI, “Aerie”), a pharmaceutical company focused on the discovery, development, manufacturing and commercialization of first-in-class...
19 months ago
Alcon ups its glaucoma game again with $770M Aerie Pharma acquisition
MedCity News
The Aerie Pharma acquisition brings Alcon two commercialized glaucoma products, as well as a pipeline of programs in various stages of...
19 months ago
Alcon acquires Aerie Pharma for £658m
Optician Online
Alcon acquires Aerie Pharma for £658m ... Alcon acquired the ophthalmic supplier Aerie Pharmaceuticals for £658m ($770m), adding to its expansion...
18 months ago
Aerie Files Three Patent Suits to Block Copies of Two Eye Drugs
Bloomberg Law News
Aerie Pharmaceuticals Inc. alleges generic versions of its eye treatment drug Rhopressa proposed by three companies, and copycats of another...
24 months ago
Alcon to acquire Aerie Pharmaceuticals
Ophthalmology Times
Alcon and Aerie Pharmaceuticals Inc. have announced the companies have entered into a definitive merger agreement through which Alcon will...
19 months ago
Aerie Pharma rockets on news of takeover bid
The Pharma Letter
The purchase price of $15.25 per share represents a premium of 37% to Aerie's last closing price and represents an equity value of approximately...
19 months ago
Aerie Pharma's 2nd Glaucoma Drug Gets FDA Approval
BioSpace
The U.S. Food and Drug Administration (FDA) approved Aerie Pharmaceuticals Rocklatan (netarsudil and latanoprost ophthalmic solution) to...
60 months ago
Alcon to Acquire Aerie Pharmaceuticals, Inc., Enhancing its Ophthalmic Pharmaceutical Portfolio
Vision Monday
Rocklatan is a fixed dose combination of the Rho kinase inhibitor, netarsudil, and a prostaglandin F2α analogue, latanoprost, indicated for the...
19 months ago